Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03408080 · ClinicalTrials.gov registry record · Phase 3
Open Pilot Trial of BHV-4157
A Phase 3 study of Spinocerebellar Ataxias and Spinocerebellar Ataxia Type 6, sponsored by University of California, Los Angeles.
- Active
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03408080 is a Phase 3 study of Spinocerebellar Ataxias and Spinocerebellar Ataxia Type 6 that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 24 participants, below the 474-participant average among 5 other Spinocerebellar Ataxias trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03408080, a Phase 3 study of Spinocerebellar Ataxias and Spinocerebellar Ataxia Type 6, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
24 adults, between the ages of 18 and 75 years, with cerebellar ataxia will be enrolled in a 12 week trial of BHV-4157 for treatment of ataxia. BHV-4157 is a pro-drug of riluzole (which is currently FDA-approved for ALS, Lou Gehrig's disease). There will be 5 visits to UCLA required--Screening when general and neurological examination, blood and urine testing, ECG, and questionnaires will be administered; Baseline when general and neurological examination and questionnaires will be administered and study drug dispensed; Week 4 and Week 12 when general and neurological examination, blood and urine testing, ECG, and questionnaires will be administered; 2 weeks after finishing study drug when general examination and blood testing will be completed. There is an option for a 36 week extension of the study drug trial.
Conditions Studied
Interventions
- DRUG BHV-4157
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2024-12-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03408080
The ClinicalTrials.gov registry entry for NCT03408080 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 5 other Spinocerebellar Ataxias trials with a reported enrollment target (95% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Spinocerebellar Ataxias appearing as the primary indexed condition, and to 1 intervention - of which BHV-4157 is the first listed.
NCT03408080 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03408080 about?
NCT03408080 is a clinical study titled "Open Pilot Trial of BHV-4157". 24 adults, between the ages of 18 and 75 years, with cerebellar ataxia will be enrolled in a 12 week trial of BHV-4157 for treatment of ataxia. BHV-4157 is a pro-drug of riluzole (which is currently FDA-approved for ALS, Lou Gehrig's disease). There will be 5 visits to UCLA required--Screening when ...
What is the current status of trial NCT03408080?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2017-12-15. Estimated completion is 2024-12-15.
What conditions does trial NCT03408080 study?
This clinical trial studies the following conditions: Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia 3.
What interventions are being tested in trial NCT03408080?
The interventions under investigation include: BHV-4157 (DRUG).
Who is sponsoring clinical trial NCT03408080?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03408080 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinocerebellar Ataxias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Troriluzole in Adult Participants With Spinocerebellar Ataxia
ACTIVE NOT RECRUITING · Phase 3
-
Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases
RECRUITING
-
Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control
ACTIVE NOT RECRUITING
-
Aerobic Exercise, Balance Training, and Ataxia
COMPLETED · NA
-
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.